BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20197467)

  • 1. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
    Watters JW; Cheng C; Majumder PK; Wang R; Yalavarthi S; Meeske C; Kong L; Sun W; Lin J; Heyer J; Ware C; Winter C; Reilly JF; Demuth T; Clark S; Chiu MI; Robinson MO; Kohl N; Kannan K
    Cancer Res; 2009 Dec; 69(23):8949-57. PubMed ID: 19903844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
    Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
    Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
    Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
    Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
    Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
    Liu M; Howes A; Lesperance J; Stallcup WB; Hauser CA; Kadoya K; Oshima RG; Abraham RT
    Cancer Res; 2005 Jun; 65(12):5325-36. PubMed ID: 15958580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
    Suwanjunee S; Wongchana W; Palaga T
    Anticancer Drugs; 2008 Jun; 19(5):477-86. PubMed ID: 18418214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
    Lewis HD; Leveridge M; Strack PR; Haldon CD; O'neil J; Kim H; Madin A; Hannam JC; Look AT; Kohl N; Draetta G; Harrison T; Kerby JA; Shearman MS; Beher D
    Chem Biol; 2007 Feb; 14(2):209-19. PubMed ID: 17317574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
    Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
    Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
    Kogoshi H; Sato T; Koyama T; Nara N; Tohda S
    Oncol Rep; 2007 Jul; 18(1):77-80. PubMed ID: 17549349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
    Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
    Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; BisarĂ² B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.